|
Comparison of clinical scoring systems in aggressive B-cell lymphomas (BCL): An individual patient-level analysis across international trials (SEAL). |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - Abbvie; Amgen; Celgene; Gilead Sciences; Janssen; Merck; MorphoSys; Novartis; Roche/Genentech; SERVIER; Takeda |
Consulting or Advisory Role - Acerta Pharma; Celgene; Epizyme; Gilead Sciences; Janssen; Kite, a Gilead company; Merck; morphosys; Novartis; Pfizer; Roche/Genentech; SERVIER |
|
|
No Relationships to Disclose |
|
|
Research Funding - 4SC (Inst); Amgen (Inst); AstraZeneca (Inst); Bayer (Inst); Celgene (Inst); Clovis Oncology (Inst); Janssen (Inst); Lilly (Inst); MedImmune (Inst); Merck (Inst); Merrimack (Inst); Sanofi (Inst) |
|
|
|
Travel, Accommodations, Expenses - Abbvie; Amgen; Roche |
|
|
Honoraria - Amgen; Gilead Sciences; Novartis; Servier/Pfizer |
Consulting or Advisory Role - Celgene; Gilead Sciences; Janssen-Cilag; Roche; Takeda |
Travel, Accommodations, Expenses - Amgen; Celgene; Roche |
|
|
Honoraria - Bristol-Myers Squibb; SERVIER |
Consulting or Advisory Role - Janssen; Karyopharm Therapeutics; Roche |
Travel, Accommodations, Expenses - Roche |
|
|
Consulting or Advisory Role - Celgene; Gilead Sciences |
Travel, Accommodations, Expenses - Amgen; Gilead Sciences; Roche |
|
|
No Relationships to Disclose |
|
|
|
|
|
Consulting or Advisory Role - Abbvie; AstraZeneca; Bayer; BeiGene; Celgene; Denovo Biopharma; Gilead Sciences; Karyopharm Therapeutics; OptumRx; Pharmacyclics/Janssen; Seagen; Spectrum Pharmaceuticals |
Research Funding - Abbvie (Inst); Acerta Pharma (Inst); BeiGene (Inst); Celgene (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); Immune Design (Inst); Infinity Pharmaceuticals (Inst); Janssen Oncology (Inst); Onyx (Inst); Pharmacyclics (Inst); TG Therapeutics (Inst) |
Travel, Accommodations, Expenses - Celgene; Genentech/Roche; Gilead Sciences |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |